These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26846019)

  • 41. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.
    Kawamura Y; Arase Y; Ikeda K; Hirakawa M; Hosaka T; Kobayashi M; Saitoh S; Yatsuji H; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2010 Oct; 123(10):951-956.e1. PubMed ID: 20920698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression of MCP/CCR2 in patients of hepatocellular carcinoma and liver cirrhosis].
    Fang N; Fan X; Zhang XS
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):553-4. PubMed ID: 19912695
    [No Abstract]   [Full Text] [Related]  

  • 43. [Hepatic carcinogenesis: prevalent role of hepatitis C virus?].
    Oberti F
    Gastroenterol Clin Biol; 1994; 18(4):394-6. PubMed ID: 7958666
    [No Abstract]   [Full Text] [Related]  

  • 44. [High risk group and screening methods of hepatocellular carcinoma].
    Matsushita E; Kaneko S; Kobayashi K
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():229-35. PubMed ID: 11761945
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of hepatitis C: advances and consensus].
    Lerebours E; Marcellin P; Dhumeaux D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B5-6. PubMed ID: 12180308
    [No Abstract]   [Full Text] [Related]  

  • 46. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
    Khokhar N; Niazi TK; Qureshi MO
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus.
    Kita Y; Mizukoshi E; Takamura T; Sakurai M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    Metabolism; 2007 Dec; 56(12):1682-8. PubMed ID: 17998021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Expression and clinical significance of Notch1 in human hepatocellular carcinoma].
    Mi LL; Yin F; Du SB; Yao SK
    Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):628-9. PubMed ID: 23227533
    [No Abstract]   [Full Text] [Related]  

  • 53. Hepatocellular carcinoma.
    Naugler WE; Schwartz JM
    Dis Mon; 2008 Jul; 54(7):432-44. PubMed ID: 18570913
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma.
    Brechot C
    Hepatology; 1997 Mar; 25(3):772-4. PubMed ID: 9049234
    [No Abstract]   [Full Text] [Related]  

  • 55. Hepatocellular carcinoma: pathogenetic implications of the hepatitis delta virus.
    Oliveri F; Colombatto P; Derenzini M; Trere D; Papotti M; David E; Negro F; Bellati G; Ideo G; D'Aquino M
    Prog Clin Biol Res; 1993; 382():165-70. PubMed ID: 8389050
    [No Abstract]   [Full Text] [Related]  

  • 56. [Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
    Tarao K
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():769-73. PubMed ID: 11762054
    [No Abstract]   [Full Text] [Related]  

  • 57. [Recurrence rates and prognosis after hepatectomy on the patients with hepatocellular carcinoma compromised with HCV hepatitis--comparison between B, BC and NBNC type].
    Une Y; Kamiyama T; Misawa K; Nakanishi K; Uchino J
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):815-20. PubMed ID: 7563882
    [No Abstract]   [Full Text] [Related]  

  • 58. Hepatitis C in the Eastern Mediterranean Region.
    Esmat G
    East Mediterr Health J; 2013 Jul; 19(7):587-8. PubMed ID: 24975301
    [No Abstract]   [Full Text] [Related]  

  • 59. [Informed consent for high risk group of hepatocellular carcinoma].
    Yamada G
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():812-6. PubMed ID: 11762062
    [No Abstract]   [Full Text] [Related]  

  • 60. A patient with hepatitis C-related cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy.
    Shibata M; Yanaga K; Morizane T; Yanagawa T; Hirakawa M; Ueno Y; Esquivel CO; Mitamura K
    J Gastroenterol; 2003; 38(6):598-602. PubMed ID: 12858850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.